Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclin E in normal and neoplastic cell cycles.

Harry C Hwang1, Bruce E Clurman

  • 1Divisions of Clinical Research and Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.

Oncogene
|April 20, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transcriptional states define dependencies and therapeutic vulnerabilities in head and neck cancer.

NPJ precision oncology·2026
Same author

Subtype-Specific Dependencies and Drug Vulnerabilities Enable Precision Therapeutics in Head and Neck Cancer.

bioRxiv : the preprint server for biology·2025
Same author

Global and context-specific transcriptional consequences of oncogenic Fbw7 mutations.

eLife·2022
Same author

Two diphosphorylated degrons control c-Myc degradation by the Fbw7 tumor suppressor.

Science advances·2022
Same author

Proteasomal degradation of the tumour suppressor FBW7 requires branched ubiquitylation by TRIP12.

Nature communications·2021
Same author

FOXM1 drives HPV+ HNSCC sensitivity to WEE1 inhibition.

Proceedings of the National Academy of Sciences of the United States of America·2020
Same journal

SNORA11B recruits SWI/SNF to suppress esophageal squamous cell carcinoma malignancy by promoting GPD1-mediated G3P accumulation and mitochondrial damage.

Oncogene·2026
Same journal

Humanized anti-Claudin-1 antibodies to treat colorectal cancer.

Oncogene·2026
Same journal

CAF-derived exosomes inhibit ferroptosis via GALNT14-mediated O-GalNAcylation of SLC7A11 in colorectal cancer.

Oncogene·2026
Same journal

SRD5A3-mediated aberrant N-glycosylation of SCARA5 promotes ferroptosis in lung adenocarcinoma.

Oncogene·2026
Same journal

Aberrant splicing in human cancer shows possible functional impact on transcription factors.

Oncogene·2026
Same journal

The crosstalk between RNA m6A modification and protein lactylation: emerging insights into tumor progression.

Oncogene·2026
See all related articles

Cyclin E-Cdk2 regulates cell cycle progression. Deregulation of cyclin E activity is common in cancer cells, playing a key role in tumor development.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Cancer Research

Background:

  • Cyclin E-Cdk2 is a key regulator of G1 phase progression in the cell cycle.
  • Recent studies challenge the established role of cyclin E in mammalian models.
  • Cyclin E activity is tightly controlled in normal cells but often dysregulated in cancer.

Purpose of the Study:

  • To review the regulation and functions of cyclin E.
  • To discuss the role of cyclin E in normal mammalian cells.
  • To explore the involvement of cyclin E in neoplastic cells and tumorigenesis.

Main Methods:

  • Literature review of existing research on cyclin E.
  • Analysis of data from mammalian models.
  • Synthesis of information on cell cycle regulation and cancer biology.

Related Experiment Videos

Main Results:

  • Cyclin E influences numerous processes critical for cell division.
  • Dysregulation of cyclin E is a hallmark of many cancers.
  • Altered cyclin E activity is implicated in the fundamental mechanisms of tumorigenesis.

Conclusions:

  • Cyclin E remains a critical factor in cell cycle control.
  • Understanding cyclin E regulation is vital for cancer research.
  • Further investigation into cyclin E's role in normal and cancerous cells is warranted.